Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
about
Potential Antiviral Agents from Marine Fungi: An OverviewProfile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelagoIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.H11/HSPB8 Restricts HIV-2 Vpx to Restore the Anti-Viral Activity of SAMHD1.A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.Antifungal and antiviral products of marine organisms.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Mortality and survival patterns of people living with HIV-2Novel inhibitors of human immunodeficiency virus type 2 infectivity.Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.Quasispecies and Drug Resistance
P2860
Q26800107-3B885CAC-01BA-4BC7-9D95-DB2762954DEFQ28538242-ACC07105-253F-49FB-B6EE-491FA18F858DQ35083423-AC674ECD-E82B-4F2D-A93F-1E3AE84498A9Q35993749-BE6D2E19-210E-46B8-A34D-45C108EE67F0Q36290647-F4B9B424-BC97-43DC-85A4-8F7506FCC870Q36996391-345C5E6D-9A14-4FB6-91CC-4160711BFF5DQ37512840-54D4D6ED-1304-4AC4-A4B6-A49EAE1EEAB7Q37517645-4C93B438-2A5C-43F0-BF88-538E201316BAQ37634178-4731384C-0F37-49D0-B61D-B0AB50A28D10Q38755690-92D2CB1C-6C1A-46D0-BDD7-5F2FCD7A7EC8Q38851677-D4EE75F4-1518-4E7D-A372-A4FFF864A791Q38967949-16341A4C-D31E-4618-9A08-C119E78DD6BEQ40261719-09F2878E-37A2-4E37-A123-3DA0C100EB5AQ40278530-921AB8AF-3242-4FEE-8775-F4B145FBABECQ40432241-AADF38F1-220C-43AB-840D-7F2F4706DEB3Q40797960-9B04777A-C646-4768-BE68-60F19B2EBBBCQ41548052-CABD821F-0E4B-4BA0-8505-C8D1B98341E7Q42318282-A59668FF-89D1-479B-8DBE-EC192DE63350Q47560712-FEC3C963-FF8F-4439-B5A6-5594DFAE053EQ56957250-E4F65563-1940-420F-B96F-28AB7F6EB128
P2860
Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiretroviral therapy and dru ...... ciency virus type 2 infection.
@en
type
label
Antiretroviral therapy and dru ...... ciency virus type 2 infection.
@en
prefLabel
Antiretroviral therapy and dru ...... ciency virus type 2 infection.
@en
P1433
P1476
Antiretroviral therapy and dru ...... iciency virus type 2 infection
@en
P2093
Luis Menéndez-Arias
Mar Alvarez
P356
10.1016/J.ANTIVIRAL.2013.12.001
P577
2013-12-15T00:00:00Z